Toxicity frequency including CRS, ICANS, neutropenia, and infections
| . | Tisa-cel (n = 50) . | Brexu-cel (n = 20) . | P value . |
|---|---|---|---|
| CRS any grade, n (%) | 28 (56) | 17 (85) | .01 |
| Maximum CRS grade, n (%) | |||
| 1 | 9 | 9 | .46 |
| 2 | 10 | 6 | |
| ≥3 | 9 | 2 | .41 |
| 3 | 6 | 2 | |
| 4 | 3 | 0 | |
| 5 | 0 | 0 | |
| ICANS any grade, n (%) | 9 (18) | 8 (40) | .05 |
| Maximum ICANS grade, n (%) | |||
| 1 | 5 | 1 | |
| 2 | 2 | 0 | |
| ≥3 | 2 | 7 | <.001 |
| 3 | 2 | 6 | |
| 4 | 0 | 1 | |
| 5 | 0 | 0 | |
| Patients receiving tocilizumab, n (%) | 12 (24) | 14 (70) | .04 |
| No. of tocilizumab doses, median (range) | 1 (1-4) | 1 (1-3) | |
| Patients receiving steroids, n (%) | 5 (10) | 12 (48) | .09 |
| Steroid exposure, median (range) | 0 days (0-16) | 13 mg (0-840) | |
| Peak serum ferritin, median (range), ng/mL | 3470 (150-238 520) | 1806 (11-28 587) | |
| Peak C-reactive protein, median (range), mg/dL | 11.4 (0-306) | 26 (0.4-285) | |
| Neutropenia after infusion | |||
| Grade 4 neutropenia, n (%) | 29 (58) | 16 (80) | .08 |
| Duration of grade 4 neutropenia, median (range), d | 13.5 (1-75) | 14 (3-39) | |
| Infections within 30 days of CAR T, n (%) | |||
| Any infection | 12 (24) | 5 (25) | .99 |
| Fungal infection | 2 (4) | 1 (5) | .88 |
| Hospital length of stay, median (range), d | 13.5 (0-53) | 14 (0-55) |
| . | Tisa-cel (n = 50) . | Brexu-cel (n = 20) . | P value . |
|---|---|---|---|
| CRS any grade, n (%) | 28 (56) | 17 (85) | .01 |
| Maximum CRS grade, n (%) | |||
| 1 | 9 | 9 | .46 |
| 2 | 10 | 6 | |
| ≥3 | 9 | 2 | .41 |
| 3 | 6 | 2 | |
| 4 | 3 | 0 | |
| 5 | 0 | 0 | |
| ICANS any grade, n (%) | 9 (18) | 8 (40) | .05 |
| Maximum ICANS grade, n (%) | |||
| 1 | 5 | 1 | |
| 2 | 2 | 0 | |
| ≥3 | 2 | 7 | <.001 |
| 3 | 2 | 6 | |
| 4 | 0 | 1 | |
| 5 | 0 | 0 | |
| Patients receiving tocilizumab, n (%) | 12 (24) | 14 (70) | .04 |
| No. of tocilizumab doses, median (range) | 1 (1-4) | 1 (1-3) | |
| Patients receiving steroids, n (%) | 5 (10) | 12 (48) | .09 |
| Steroid exposure, median (range) | 0 days (0-16) | 13 mg (0-840) | |
| Peak serum ferritin, median (range), ng/mL | 3470 (150-238 520) | 1806 (11-28 587) | |
| Peak C-reactive protein, median (range), mg/dL | 11.4 (0-306) | 26 (0.4-285) | |
| Neutropenia after infusion | |||
| Grade 4 neutropenia, n (%) | 29 (58) | 16 (80) | .08 |
| Duration of grade 4 neutropenia, median (range), d | 13.5 (1-75) | 14 (3-39) | |
| Infections within 30 days of CAR T, n (%) | |||
| Any infection | 12 (24) | 5 (25) | .99 |
| Fungal infection | 2 (4) | 1 (5) | .88 |
| Hospital length of stay, median (range), d | 13.5 (0-53) | 14 (0-55) |